Joan Huaqiong Shen, M.D., Ph.D., is a US Board-certified physician and holds a PhD in life sciences from Indiana University School of Medicine where she had fellowship trainings in endocrinology, psychopharmacology and clinical pharmacology and where she and was appointed as an adjunctive professor in the department of psychiatry. Joan also had postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology in the Unite States.

Dr. Shen serves in many executive positions in Eli Lilly &Company, Wyeth, Pfizer, Hengrui and Johnson & Johnson, such as the China clinical head at Pfizer, Chief Medical Officer at Jiangsu Hengrui Medicine and China Development Head of Janssen Pharma J&J. In Hengrui, she built the largest clinical team among domestic pharma companies and led successful trials in China, US and Australia. At Janssen, She oversaw all clinical development programs in China. She gained rich experiences of working with FDA, EMEA, CNDA (previously CFDA), PMDA, KFDA and etc.  Joan joined I-Mab biopharma as the head of R&D in 2017.

Dr. Shen was elected for the co-chair of RDPAC’s R&D core team and was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program”. She also sits in the executive committee of China New Drug Research Evaluation Committee. She holds academic positions as the guest professor of Beijing University Clinical Research Institute.